mynth
← DATABASE
12/2021100%

Pharmaouest Industries acquired by Winncare

FRANCE Life Sciences / Medical Devices REV €10–30M

Context

This transaction marks the first major structural acquisition for Winncare following the entry of Siparex ETI as its majority shareholder earlier in 2021. By acquiring 100% of Pharmaouest Industries, Winncare has significantly strengthened its industrial capabilities and product portfolio in the high-stakes segment of pressure ulcer prevention. This horizontal integration allows Winncare to internalize advanced visco-elastic foam manufacturing technologies and leverage Pharmaouest's dual-site industrial setup in France and Tunisia to optimize its supply chain. The rationale for the merger is driven by the complementarity of the two groups, product lines and customer bases. The addition of Pharmaouest provides Winncare with a specialized R&D pipeline and a wider range of medical consumables specifically tailored for home care and elderly care institutions. Strategically, this acquisition acted as a catalyst for Winncare's growth, contributing to a 50% increase in the group's total revenue within the same fiscal year. The operation aligns with Winncare's long-term goal of becoming a diversified European leader in medical equipment by consolidating smaller, specialized manufacturers with high technical value. This deal also supports the group's commitment to a mission-driven corporate model, focusing on social impact and patient-centric innovation throughout the care journey.

Pharmaouest Industries, which reported an EBITDA margin of [members only] in 2021, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

Pharmaouest Industries is a prominent French manufacturer specializing in medical devices for pressure ulcer prevention and patient comfort, primarily serving the home care (MAD) and nursing home (EHPAD) sectors. The company possesses recognized technical expertise in the formulation and processing of visco-elastic foam, a critical component for high-performance therapeutic surfaces. Its business model is supported by a robust industrial footprint, featuring a specialized production plant in Ille-et-Vilaine and an additional industrial facility in Tunisia, providing the group with significant production capacity and cost-efficiency. Pharmaouest,s value proposition centers on its ability to deliver innovative, high-quality medical foam products that meet the specific clinical requirements of long-term care facilities. The company,s strategy focuses on continuous product development to enhance the patient care pathway, ensuring safety and skin integrity for individuals with reduced mobility. By maintaining control over its manufacturing process, Pharmaouest ensures high responsiveness to the evolving needs of healthcare providers and institutional distributors across the French and international markets.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2021
€10–30M
[members only]
[members only]
2020
€10–30M
[members only]
[members only]

Other operations with Winncare

Other operations with Winncare
DateAcquirerTargetCountrySector
03/2026SIPAREXWINNCAREFRANCEMedical Devices
02/2021SIPAREXWINNCAREFRANCEMedical Devices

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
01/2022ANJAC BEAUTY & HEALTHAPOLLO HEALTHCARE CORP..CANADACDMO
01/2022PERMIRABIO PRODUCTS LABORATORY (BPL)UNITED KINGDOMCDMO
12/2021THE CARLYLE GROUP / GTCRRESONETICSUNITED STATESMedical Devices
12/2021PLANMECA GROUPKAVO DENTALGERMANYMedical Devices
12/2021INTEGEROSCORUNITED STATESImplants & Prosthetics
11/2021ESSLING CAPITAL / MULTICROISSANCE / BOURRELIER GROUPTEKNIMEDFRANCEImplants & Prosthetics
11/2021COLOPLASTATOS MEDICALSWEDENMedical Consumables
09/2021PERRIGO COMPANYHRA PHARMAFRANCEGenerics / Labs
07/2021MONTAGU PRIVATE EQUITYINTECH MEDICALFRANCEImplants & Prosthetics
07/2021PARTNERS GROUPPHARMATHENGREECECDMO

REFERENCES

Revenue range: REV €10–30M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Pharmaouest Industries by Winncare are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers Winncare’s acquisition of 100% of Pharmaouest Industries, a French company specialised in Medical Devices, in 2021.

What was Pharmaouest Industries’s revenue at the time of the deal?

At the time of the transaction, Pharmaouest Industries’s annual revenue was estimated within the €10–30M range (FY 2021). Detailed financial figures are available to members.

What sources support the information on this transaction?

The details of this transaction are sourced directly from the official corporate announcement published on the parties’ institutional website, ensuring primary-source verification of the closing and perimeter.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.